FDA ·
Congressional oversight of FDA's compounded drug policy intensified throughout 2025 and 2026. The House Energy and Commerce Subcommittee on Health held hearings in May 2025 and February 2026 examining compounded GLP-1 policy, the FDA's enforcement resources, and the balance between patient access and drug approval integrity. Senate HELP Committee oversight has similarly addressed the topic. Various bills have been introduced — some aimed at expanding compounding authority, others at restricting it — but as of early 2026 no major compounding legislation has passed. The political dynamics around RFK Jr.'s peptide-friendly stance at HHS have added a distinctive dimension to these discussions.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.